Carisoprodol elimination in humans - PubMed

Carisoprodol elimination in humans

H Olsen et al. Ther Drug Monit. 1994 Aug.

Abstract

The elimination of the muscle relaxant drug, carisoprodol, was examined in 10 healthy volunteers after an oral dose of 700 mg. In nine subjects, carisoprodol was rapidly eliminated, with a mean half-life of 99 +/- 46 min, and extensively converted to meprobamate. Within 2.5 h after carisoprodol intake, meprobamate serum concentrations exceeded those of carisoprodol. Serum levels of meprobamate recorded (15-25 mumol/L) indicate that meprobamate might contribute to the effect(s) of carisoprodol. One subject eliminated carisoprodol with an overall half-life of 376 min, and only small amounts of meprobamate were recorded. This subject was found to be a poor metabolizer of mephenytoin. In spiked human sera, protein binding of carisoprodol was in the range of 41-67%, whereas meprobamate was bound to a lesser extent, 14-24%.

Similar articles

• Formation of meprobamate from carisoprodol is catalysed by CYP2C19.

  Dalén P, Alvan G, Wakelkamp M, Olsen H. Dalén P, et al. Pharmacogenetics. 1996 Oct;6(5):387-94. doi: 10.1097/00008571-199610000-00002. Pharmacogenetics. 1996. PMID: 8946470

• Pharmacokinetic modeling of carisoprodol and meprobamate disposition in adults.

  Lewandowski TA. Lewandowski TA. Hum Exp Toxicol. 2017 Aug;36(8):846-853. doi: 10.1177/0960327116672912. Epub 2016 Oct 10. Hum Exp Toxicol. 2017. PMID: 27758843

• Carisoprodol (Soma): a new and cautious perspective on an old agent.

  Littrell RA, Hayes LR, Stillner V. Littrell RA, et al. South Med J. 1993 Jul;86(7):753-6. doi: 10.1097/00007611-199307000-00006. South Med J. 1993. PMID: 8322081 Review.

• Carisoprodol - Effects on Human Performance and Behavior.

  Robertson MM, Marinetti LJ. Robertson MM, et al. Forensic Sci Rev. 2003 Jan;15(1):1-9. Forensic Sci Rev. 2003. PMID: 26256591 Review.

Cited by

• Single and Multiple Dose PK-PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers.

  Calvo A, Alonso S, Prieto E, Ascaso-Del-Rio A, Ortuño J, Fernandez N, Portolés A. Calvo A, et al. J Clin Med. 2022 Feb 6;11(3):858. doi: 10.3390/jcm11030858. J Clin Med. 2022. PMID: 35160309 Free PMC article.

• Carisoprodol tolerance and precipitated withdrawal.

  Gatch MB, Nguyen JD, Carbonaro T, Forster MJ. Gatch MB, et al. Drug Alcohol Depend. 2012 Jun 1;123(1-3):29-34. doi: 10.1016/j.drugalcdep.2011.10.010. Epub 2011 Nov 4. Drug Alcohol Depend. 2012. PMID: 22055010 Free PMC article.

• Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

  Bertz RJ, Granneman GR. Bertz RJ, et al. Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004. Clin Pharmacokinet. 1997. PMID: 9084960 Review.

• Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma.

  Paul G, Parshotam GL, Garg R. Paul G, et al. J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):387-8. doi: 10.4103/0970-9185.173346. J Anaesthesiol Clin Pharmacol. 2016. PMID: 27625493 Free PMC article.

• Abuse Potential of Soma: the GABA(A) Receptor as a Target.

  Gonzalez LA, Gatch MB, Forster MJ, Dillon GH. Gonzalez LA, et al. Mol Cell Pharmacol. 2009 Jan 1;1(4):180-186. Mol Cell Pharmacol. 2009. PMID: 20419052 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database